Why is lune barefoot

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Yes, preimplantation genetic testing (PGT) can be performed on fresh embryos. This advanced reproductive technology allows for the screening of embryos for genetic abnormalities before they are transferred to the uterus. While often associated with frozen embryos, PGT is also a viable and increasingly common option for fresh embryo transfers.

Key Facts

PGT can be performed on embryos at various developmental stages, including the cleavage stage (day 3) and blastocyst stage (day 5-6).
The biopsy procedure for PGT involves removing a small number of cells from the embryo.
PGT helps identify chromosomal abnormalities (aneuploidy) and specific genetic disorders.
The success rates of PGT-tested embryos are often higher than untested embryos, leading to improved implantation rates.
PGT can be performed on both fresh and frozen embryos, offering flexibility in fertility treatments.

Overview

Preimplantation Genetic Testing (PGT) is a groundbreaking suite of techniques employed in assisted reproductive technologies (ART) to screen embryos for genetic abnormalities before they are transferred to the uterus. This significantly enhances the chances of a successful pregnancy and reduces the risk of genetic disorders in offspring. While PGT is often discussed in the context of frozen embryos, a crucial aspect is its applicability to fresh embryos, meaning embryos that are biopsied and tested shortly after fertilization without undergoing a freezing and thawing cycle.

The decision to use PGT, whether on fresh or frozen embryos, is typically made in consultation with a fertility specialist and a genetic counselor. Factors such as parental age, a history of recurrent miscarriages, previous failed IVF cycles, or known genetic conditions within the family all play a role in determining its suitability. The advancements in PGT technologies have made it a more accessible and reliable tool for couples seeking to optimize their IVF outcomes.

How It Works

Embryo Development and Biopsy: After in vitro fertilization (IVF), embryos are cultured in the laboratory. Depending on the specific PGT protocol and the stage of embryo development, a small number of cells are carefully removed for analysis. For embryos at the cleavage stage (typically day 3 after fertilization), one or two cells (blastomeres) are biopsied. For embryos at the blastocyst stage (typically day 5 or 6), several cells from the trophectoderm (the outer layer that will form the placenta) are removed. The blastocyst stage biopsy is generally preferred as it yields more cells and is less invasive to the inner cell mass, which will form the fetus.
Genetic Analysis: The biopsied cells are then sent to a specialized genetics laboratory for analysis. The primary types of PGT include: PGT-A (formerly PGS) for aneuploidy screening, which checks for the correct number of chromosomes; PGT-M (formerly PGD) for monogenic/single gene defects, which screens for specific inherited genetic disorders like cystic fibrosis or Huntington's disease; and PGT-SR for chromosomal rearrangements, which identifies embryos with structural chromosomal abnormalities like translocations. Advanced techniques like next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH) are commonly used for comprehensive analysis.
Embryo Transfer Decision: Based on the genetic test results, embryos are classified as either chromosomally normal (euploid) or abnormal (aneuploid/affected). Only euploid embryos are then selected for transfer back into the woman's uterus. The selection of euploid embryos aims to increase the likelihood of implantation, reduce the risk of miscarriage, and prevent the transmission of specific genetic diseases.
Fresh vs. Frozen Embryo Transfer: With fresh embryo transfers, the embryo biopsy and genetic testing are performed on embryos that have not been frozen. If PGT is conducted, the embryo transfer typically occurs after the genetic results are available, usually within the same IVF cycle. In contrast, for frozen embryo transfers, embryos are biopsied, genetically tested, and then cryopreserved. The transfer then takes place in a subsequent cycle after the embryo has been thawed and confirmed to be viable. While both approaches are effective, the choice between fresh and frozen transfer with PGT can depend on various factors, including the individual's ovarian response, the risk of ovarian hyperstimulation syndrome (OHSS), and the clinic's protocols.

Key Comparisons

Feature	PGT on Fresh Embryos	PGT on Frozen Embryos
Timing of Transfer	Typically within the same IVF cycle after genetic results are obtained.	In a subsequent cycle after thawing the embryo.
Potential for OHSS Mitigation	May carry a slightly higher risk of OHSS in sensitive individuals if transfer occurs in the same cycle.	Generally preferred for individuals at high risk of OHSS as the transfer is in a later cycle.
Embryo Viability Post-Biopsy	Assessed for health and viability immediately after biopsy for potential fresh transfer.	Assessed for health and viability after biopsy and then re-assessed after thawing.
Clinic Protocol Influence	Often dictated by clinic protocols aiming for timely transfer after testing.	Allows for more flexibility in scheduling the transfer cycle.
Comprehensive Chromosomal Screening	Yes, allows for advanced testing like PGT-A, PGT-M, and PGT-SR.	Yes, allows for advanced testing like PGT-A, PGT-M, and PGT-SR.

Why It Matters

Impact on Success Rates: Studies have shown that transferring chromosomally normal embryos, identified through PGT, can significantly increase implantation rates and reduce the incidence of early miscarriages. For women of advanced maternal age, where the risk of aneuploidy increases, PGT can be particularly beneficial in selecting viable embryos, potentially leading to a live birth more efficiently.
Reducing Genetic Disease Transmission: For couples who are carriers of specific genetic disorders or have a family history of such conditions, PGT-M offers the ability to identify and exclude embryos that would be affected by the disease. This provides a crucial option for family planning, allowing them to have children free from specific inherited conditions.
Minimizing IVF Cycle Failures: By selecting only euploid embryos for transfer, PGT can help to reduce the number of failed IVF cycles. This not only saves time and emotional distress but also can be more cost-effective in the long run by avoiding multiple transfers of chromosomally abnormal embryos that are unlikely to result in a successful pregnancy.

In conclusion, the ability to perform PGT on fresh embryos is a vital component of modern fertility treatment. It empowers individuals and couples with greater control over their reproductive choices, offering a scientifically driven approach to maximize the chances of a healthy pregnancy and a healthy baby. The continuous evolution of PGT technology promises even more refined and effective applications in the future.